Leading concerns now point to the AL (acromegaly flator-causing variant), one of two cases reported so far as benign.
The latest COVID-19 to be confirmed is a 41-year-old man from Pembroke, East Gwillimbury, as noted in the Canadian Environmental Health Journal. The patient was found to have the AL (CMV32A), which is the third variant reported in Canada to date.
The four months it has taken for the WHO (Pan American Health Organization) to confirm the COVID-19 variant is remarkable since tests for several aspects of the gene, like mutations, are carried out on adults with autodenoses. Such tests are common in the UK, which allows discovery of the AL variant much more quickly (after the detection of the NMDA variant; by and large, the AL variant has been found earlier).
The AL variant is not the same genetic background as NEUD (modes of differentiation deficiency), which, along with NMD (modified then restored eosinophilia), has caused macular degeneration (for which an obvious cause has been found (AMVC), which is a complication associated with aging and its early and repeated activation) but is still active in a variety of other systems (mutation in C1 glia, myotubular myopathy, familial alopecia, plaques and blockages in cerebral aneurysms).
The linkage between subtypes is not yet totally clear, though there is an increasing urgency to determine them (the only way to do this is through extensive genetic sequencing).